Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Reuters01-12

<a href="https://laohu8.com/S/CATX">Perspective Therapeutics</a> Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Perspective Therapeutics Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2026). The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623727-en) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602514610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602514610","market":"us","top_or_hot":-1,"title":"Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Perspective <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2026). The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623727-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Perspective <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2026). The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623727-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL67jFJt:1","article_id":"2602514610","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602514610","pubTimestamp":1768219230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Perspective Therapeutics Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium . The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","CATX":"Perspective Therapeutics","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念"},"translate_title":"Perspective Therapeutics通过强劲的患者招募和积极的早期结果推进VMT-α-NET临床计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CATX":0.9},"content_text":"Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results\n    \n\n        Perspective Therapeutics Inc. has announced business updates and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company reported continued strong patient recruitment for its lead program, VMT-α-NET, which targets neuroendocrine tumors. Updated interim data from a multi-center, open-label dose-finding study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors were presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2026). The results indicate that VMT-α-NET continues to be well-tolerated and demonstrates durable disease control with longer follow-up. Clinical updates for additional programs, including VMT01 for melanoma and PSV359 for FAP across multiple solid tumors, are expected in mid to late 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623727-en) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602514610","isCrawlerRequest":true}